论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Jiang S, Xu J, Zhuo Z, Hua Z
Received 14 October 2016
Accepted for publication 21 December 2016
Published 10 January 2017 Volume 2017:10 Pages 303—310
DOI https://doi.org/10.2147/OTT.S124690
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 4
Editor who approved publication: Dr Carlos Vigil Gonzales
Abstract: Methylenetetrahydrofolate reductase (MTHFR) is a central enzyme involved
in folate metabolism and plays an important role in DNA synthesis and
methylation. Several studies have been conducted to illustrate the associations
between MTHFR C677T and A1298C polymorphisms with
oral cancer susceptibility; however, the results are inconsistent. Therefore,
we conducted an updated meta-analysis to obtain a more reliable estimation of
the associations. We retrieved eligible studies from PubMed, EMBASE, and CBM
databases through September 2016. Ultimately, pooled analyses involved 10
studies with 1443 cases and 1640 controls for the C677T polymorphism, as well
as five studies with 973 cases and 1024 controls for the A1298C polymorphism.
Risk estimates were presented as odds ratios (ORs) and 95% confidence intervals
(95% CIs). Pooled results indicated that neither C677T nor A1298C polymorphism
was associated with oral cancer susceptibility. However, a borderline
significant association was detected between MTHFR C677T polymorphism and a decreased
oral cancer risk (homozygous model: OR=0.71, 95% CI=0.50–1.00) in
hospital-based studies. Our results suggested that MTHFR C677T and A1298C
polymorphisms might not be associated with oral cancer risk. However, more
evidence is needed to further confirm these findings in the future.
Keywords: MTHFR , polymorphisms, oral
cancer, susceptibility, meta-analysis